Shortcuts to Discovery and Characterization of Monoclonal Antibodies
Monoclonal antibody (mAb) discovery and characterization often face significant delays due to iterative screening cycles, late-stage functional failures, and downstream analytical bottlenecks. This webinar details five practical shortcuts that accelerate timelines from target validation to preclinical characterization.
The session will cover how direct monoclonal antibody protein sequencing enables rapid proof-of-concept modeling, how polyclonal antibody sequencing delivers high-success hit generation by starting with proven functional antibodies, and how early SPR-based screening and high-capacity LC-MS characterization remove common R&D bottlenecks in biotherapeutic and biosimilar development.
Speaker: Iain Rogers
VP Commercial | Rapid Novor
Iain Rogers is VP Commercial at Rapid Novor, specializing in mass spectrometry and proteomics. He began his career in mass spectrometry data analysis in 2005 and brings 15+ years of sales and marketing leadership experience. He has founded and exited two startups and earned master’s degrees from Cornell University and Queen’s University. At Rapid Novor, he leads the commercialization of the company’s technology and has been invited to speak at several biotechnology and business conferences worldwide.
Key Learning Objectives:
- Accelerate Proof-of-Concept by reformatting, switching species, or conjugating benchmark antibodies through direct monoclonal antibody sequencing.
- Shortcut Hit Discovery by using de novo polyclonal antibody sequencing to identify functional candidates from proven antibody pools.
- Streamline Down-Selection using high-throughput SPR and epitope mapping to select candidates early.
- Clear Analytical Bottlenecks with high-capacity LC-MS services for faster preclinical characterization and production decisions.
- Generate Specific Anti-IDs using polyclonal antibody sequencing for biosimilar PK/PD and ADME studies.
Who Should Attend?
- R&D Directors & Principal Scientists working in biotherapeutic and diagnostic research.
- Antibody Discovery & Biologics Teams seeking faster hit-to-lead and proof-of-concept strategies.
- Biosimilar Developers involved in anti-idiotype discovery, PK/PD, ADME, and regulatory characterization.
- Analytical & Mass Spectrometry Leads managing preclinical and early-stage characterization workflows.
- CROs & Contract Development Teams offering antibody sequencing, SPR screening, and characterization services.
Benefits of Attending:
- De-Risk Pipelines Early by testing functional concepts with reformatted benchmark antibodies before major discovery investments.
- Higher Hit Quality by starting with functional polyclonals and early SPR screening to reduce downstream candidate failures.
- Unblock Internal MS Capacity by offloading critical LC-MS characterization workloads to keep preclinical schedules on track.
- Biosimilar Advantage by gaining insights into anti-idiotype antibody generation for regulatory PK/PD and ADME compliance.